Printer Friendly

Classification, Morphology, Molecular Pathogenesis, and Outcome of Premalignant Lesions of the Pancreas.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal epithelial malignancies. With a disappointing 5-year survival rate of only 7%, PDAC is predicted to become the second leading cause of cancer death in the United States by the year 2030. (1) Although these statistics are grim, ongoing clinical studies continue to improve methods of treating this malignancy using surgical, chemotherapeutic, and radiologic means. The best treatment, of course, is prevention, and the ability to prevent disease depends on an understanding of the mechanisms that drive pancreatic neoplasia from its earliest forms.

We now know that PDAC is similar to colorectal carcinoma in that many years pass between the first cellular mutation that initiates the neoplastic process and the moment of tissue invasion. (2) We also have the ability to recognize precursor lesions in the pancreas both radiologically and histologically. Finally, we understand many of the stepwise genetic mutations that drive the sequence from precursor to invasive PDAC. With these data, the goal is to find and cure precursor lesions before the moment of invasion.

The purpose of this review is to provide an overview of the known PDAC precursor lesions and to discuss the importance of morphology and genetic mutations to patient outcome.


Cystic lesions of the pancreas are common, and with ever-improving radiologic techniques, many are discovered incidentally during imaging for another indication. (3) Although some pancreatic cysts do not pose a risk to the patient, intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), and intraductal tubulopapillary neoplasm are true neoplasms that can progress to PDAC. Excitingly, we now know that the earlier we can detect, correctly classify, and treat these cystic neoplasms, the less likely they are to progress to invasive PDAC.

Intraductal Papillary Mucinous Neoplasm

Clinical Findings and Preoperative Diagnosis.--Intraductal papillary mucinous neoplasms are grossly visible cystic neoplasms (>1 cm) that communicate with the pancreatic ductal system. The cysts are lined by neoplastic mucinous columnar epithelium that often forms papillary structures that protrude into the cyst. (4) Although IPMNs may occur anywhere in the pancreas, they are more common in the pancreatic head. These neoplasms are equally prevalent in men and women, and the usual age of diagnosis is 60 to 70 years. (5-7)

Many IPMNs are discovered incidentally in asymptomatic patients, whereas other IPMNs come to clinical attention because they produce abdominal-localizing symptoms including abdominal pain, weight loss, pancreatitis, diarrhea (secondary to pancreatic exocrine insufficiency), jaundice, nausea/vomiting, and new-onset diabetes mellitus (secondary to pancreatic endocrine insufficiency). (5,7,8) Radiologic features that favor a diagnosis of IPMN over other cystic lesions include involvement of the duct system, dilation of the main pancreatic duct, clusters of cysts indicating dilated branch ducts, and surrounding parenchymal atrophy. (9) An endoscopic ultrasound is often performed with the aim of confirming the IPMN diagnosis. The finding of mucin excretion from the ampulla of Vater (fish-mouth appearance) is practically pathognomonic for IPMN. (6,10) Endoscopic ultrasound also allows for fine-needle aspiration of the lesion and for cyst fluid sampling.

The hallmark feature in cytology for a neoplastic mucin-producing cyst (either MCN or IPMN) includes the presence of thick extracellular mucin (neoplastic mucin; Figure 1, a). (11,12) Stelow et al (13) reviewed the fine-needle aspirations of 31 IPMNs and found extracellular mucin in a majority of these lesions. Other cytologic features for IPMN (and MCN) include mucinous glandular epithelial cells in groups, papillary clusters, single cells with varying degrees of cytologic atypia, and cyst debris (Figure 1, b). The aspirate samples can be cellular or paucicellular, with high-grade lesions demonstrating increased cellularity and decreased mucin. The lining epithelium of an IPMN can be of gastric-foveolar, intestinal, oncocytic, or pancreaticobiliary types, but definite characterization of the lining epithelium is not required in the cytologic evaluation.

Genevay et al (12) evaluated 112 histologically confirmed mucin-producing cysts of pancreas and demonstrated that high-grade atypia on cytologic evaluation was the most sensitive predictor of malignancy in mucinous cysts. High-grade dysplasia is defined by the presence of atypical epithelial cells that are arranged in 3-dimensional aggregates, small papillary clusters, or single epithelial cells with a loss of the normal honeycomb architecture (Figure 1, c), with increased nuclear to cytoplasmic ratio, irregular nuclear membranes, abnormal chromatin pattern, crowding, and molding, with or without intracellular mucin (Figure 1, d). Cysts demonstrating high-grade dysplasia may also show background tumoral necrosis.

In addition to cytologic evaluation from a fine-needle aspiration specimen, cyst fluid analysis for carcinoembryonic antigen and amylase levels is extremely helpful in the diagnosis of neoplastic mucin-producing pancreatic cysts. An elevated cyst fluid carcinoembryonic antigen level reflects the presence of mucinous epithelium and is seen in both MCNs and IPMNs. Brugge et al (14) reported that a cutoff carcinoembryonic antigen level of 192 ng/mL has a 73% sensitivity and 84% specificity in differentiating mucinous from nonmucinous pancreatic cysts. This same study (14) found that among all the pancreatic cyst fluid diagnostic parameters currently in use, carcinoembryonic antigen concentration was the most accurate test for the diagnosis of a nonmalignant mucinous cyst, even more so than cytologic evaluation. Because IPMNs are connected to the pancreatic ductal system, amylase levels may also be elevated in this neoplasm and may be useful in differentiating IPMN from MCN. (15)

Risk of an Associated Invasive Cancer.--The risk of an IPMN having associated invasive carcinoma varies depending on the location and size of the cystic lesion. Clinical and radiologic criteria are used to assess this risk preoperatively, and approximately 30% of IPMNs that are surgically resected ultimately demonstrate invasive disease. (16-20) A subset of IPMNs are not recommended for surgical resection because they are at low risk of progression; these include small, branch-duct IPMNs. (3) Clinical symptoms related to the pancreas, such as abdominal pain, jaundice, and weight loss, are worrisome for an associated invasive PDAC. Imaging features that are more often seen in IPMN with an associated PDAC include main pancreatic duct or distal common bile duct dilation (Figure 2, a), cysts larger than 3.0 cm, numerous cysts, and the presence of a solid component or mural nodule. (8,19,21,22) The single most important factor for the surgical pathologist to evaluate in resected pancreata with IPMN is the presence or absence of an associated invasive carcinoma. This starts with a careful gross evaluation for the presence or absence of mural or parenchymal masses, and extends to thorough, if not complete, sampling of the IPMN for histology.

One way to classify IPMNs, although in and of itself not prognostically significant, is by the type of mucinous lining seen on histologic examination. (23) The 4 histologic subtypes of IPMN are gastric (Figure 2, b), intestinal (Figure 2, c), pancreatobiliary (Figure 2, d), and oncocytic; these may be found in isolation or be mixed within a single lesion. (4,8,24,25) Gastric-type IPMNs tend to have an undulating (rather than papillary) lining. The cells are cuboidal to columnar with small, basally oriented nuclei and a foveolar mucin cap identical to the foveolar mucinous cells present in gastric mucosa. Intestinal-type IPMNs unsurprisingly resemble colonic mucosa, with cigar-shaped nuclei, villouslike papillae, and often colonic-type goblet cells. Pancreatobiliary IPMNs have increasing architectural complexity with papillae and sometimes bridging or cribriforming of the epithelial lining. The cells themselves are more cuboidal than columnar, with basophilic cytoplasm, minimal mucin, and enlarged nucleoli. In contrast, oncocytic IPMNs, also known as intraductal oncocytic papillary neoplasms, are characterized by cells with abundant eosinophilic cytoplasm; however, like the pancreatobiliary subtype, they also contain cells with atypical nuclei forming complex architecture. (24)

Intraductal papillary mucinous neoplasms with the intestinal or pancreatobiliary subtypes are more likely to harbor an associated invasive PDAC, whereas purely gastric IPMNs are the least likely to have an associated invasive malignancy. The invasive PDACs that arise in intestinal-type IPMNs can be tubular or colloid. Additionally, intestinal-type IPMNs more often involve the main pancreatic duct, whereas branch-duct-type IPMNs usually show gastric-type differentiation. (26,27) These distinctions in epithelial subtype may be useful in conjunction with other features for preoperative planning; however, a substantial minority of IPMNs have been shown to demonstrate a mixed or unclassifiable phenotype when the completely resected cyst is present for evaluation. Because of the heterogeneity inherent in this neoplasm, the clinical and prognostic utility of epithelial subtypes is limited. (25)

The degree of dysplasia, low versus high, should also be documented. (28) In general, as an IPMN progresses from low-grade to high-grade dysplasia and eventually to invasive PDAC, cytologic and architectural atypia increase within the lesion. Nuclei in high-grade dysplastic lesions are larger, more irregular, and more hyperchromatic than their low-grade counterparts. Additionally, high-grade nuclei show "loss of polarity," or stratification, rather than sitting along the basement membrane. Finally, the architecture of a high-grade IPMN has increased complexity of papillary structures and cribriforming. (24) Gastric IPMNs are usually low-grade lesions, intestinal-type IPMN may be low or high grade, but pancreatobiliary and oncocytic IPMN are almost always high grade. (28) Oncocytic IPMNs are distinct from the pancreatobiliary type in that even if an associated invasive PDAC is present, patients tend to have a better outcome, but these data are limited by the rarity of this subtype. (27,29,30)

Clinical Importance of Pathologic Findings and Management Recommendations.--The above categorizations and attempts to calculate risk for a particular patient have grown out of our increased understanding of the natural history of IPMNs. First, patients who have invasive PDAC associated with an IPMN have an estimated 5-year survival of approximately 30% to 50%. Although this is a better prognosis than that of patients who have PDAC in the absence of a concurrent IPMN, it is a much lower survival rate than that of patients who have a noninvasive IPMN, who have an estimated 5-year overall survival of 70% to 90%. (7,18,31) For this reason, extensive sampling of an IPMN with adjacent pancreatic parenchyma is vital for accurate diagnosis and prognostication. (23) Second, IPMNs are often multifocal, and patients are therefore at risk for both synchronous and metachronous disease throughout the entire pancreas. (6,20,32) In a patient who has undergone partial pancreatic resection for a noninvasive IPMN, the risk of recurrence or new disease in the remnant pancreas is less than 20%. (7,33,34) In contrast, patients who are found to have invasive PDAC with an IPMN have a recurrence rate of almost 50%, usually as metastatic disease. (35) These data highlight the critical importance of following patients, even those with noninvasive disease, after surgery. Although adequate data are lacking for firm recommendations for follow-up of patients who have partial pancreatectomy, the consensus recommendations are currently for at least repeat examinations at 2 years and 5 years postoperatively. (20,36)

Genetic Alterations and Molecular Diagnostics.--The genetic alterations found in IPMN parallel, to a large extent, those found in invasive PDAC, with 2 differences: GNAS and RNF43 are more commonly present in IPMNs and their associated invasive cancers than in invasive PDACs not associated with an IPMN precursor. The discovery of the GNAS oncogene mutation is exciting for 2 reasons. First, GNAS mutations appear to be specific for IPMN when compared with other cystic lesions of the pancreas. Second, patients with McCune-Albright syndrome have postzygotic GNAS mutations resulting in mosaicism, and recent data indicate that these patients may have a higher incidence of IPMN than the general population and therefore may warrant increased surveillance. (6,37-39) As with invasive PDAC, activating point mutations in KRAS occur in IPMN, most often at codon 12. This appears to be an early event in IPMN formation, and KRAS mutations are found in the majority of grossly visible and even smaller (<1 cm) "incipient" IPMNs. (37,40) A variety of other genetic alterations can be found in IPMNs: LKB1/STK11, PK3CA, RNF43, p16/ CDKN2A, TP53, and SMAD4/DPC4. (30,41-44)

The importance of the above findings cannot be overstated. First, increased understanding of molecular alterations within IPMNs provides insight into the pathogenesis, spread, and progression of this neoplasm. A recent study by Pea et al (32) used targeted DNA sequencing to investigate the relationships between primary IPMN and progressive disease, including invasive PDAC, in 13 patients who underwent initial IPMN resection followed by completion pancreatectomy at a later date. The authors found that, based on the mutational profile of the neoplasms within the same patient, 7 patients had likely independent lesions, 3 patients had likely related lesions, and 3 patients had lesions of an indeterminate relationship. Only 1 of 8 patients with a negative resection margin had a likely related progressive lesion. Two of 5 patients with a positive resection margin showing high-grade dysplasia had likely related progressive lesions; the remaining 3 patients with positive margin had low-grade dysplasia and did not have genetically related progressive lesions. These results suggest 3 possibilities for IPMN progression in the remnant pancreas. First, as in the patients with high-grade dysplasia at the margin, a patient may have transection of a single neoplasm, and the portion of the transected neoplasm that remains in the remnant pancreas later recurs as a mass. Second, as in the patients with negative margins but related lesions, there may be intraductal "metastasis" of a primary lesion. In these cases, the presence of a negative margin highlights the skip nature of these neoplasms. Finally, as in the patients with genetically distinct neoplasms, there may be independent growth of multiple primary IPMNs. (32) As mentioned before, but worth reemphasizing here, these data highlight the importance of clinically following patients after the resection of an IPMN.

Increased understanding of molecular alterations within IPMNs is also valuable because the mutations can help guide preoperative diagnosis and management. Recent studies of cyst fluid obtained from IPMNs during endoscopic ultrasound have shown that molecular markers can accurately differentiate IPMNs from other cystic lesions of the pancreas. (39) Because of the high specificity of GNAS for IPMN, the presence of GNAS in cyst fluid is diagnostic of an IPMN. (39,45) Mutations in RNF43 are similarly specific for IPMN. (39) Additionally, because IPMNs connect with the ductal system of the pancreas, secretin-stimulated pancreatic juice collected from the ampulla of Vater during endoscopic ultrasound can also be analyzed for mutations associated with high-grade dysplasia and invasive PDAC. (46) Finally, a recent study of cyst fluid telomerase activity shows promise for predicting the presence of high-grade dysplasia or invasive carcinoma associated with a cystic lesion. (47) As these molecular diagnostics become incorporated into clinical practice, we will be better able to provide appropriate preoperative clinical recommendations for patients with pancreatic cysts.

Mucinous Cystic Neoplasm

Clinical Findings and Preoperative Diagnosis.--Mucinous cystic neoplasms are grossly visible cystic neoplasms that, in contrast to IPMNs, do not communicate with the pancreatic ductal system. Mucinous cystic neoplasms are lined by neoplastic mucinous columnar epithelium with an underlying distinctive and pathognomonic spindle cell ovarian-type stroma (Figure 3, a and b). This type of cyst is much more common in the body or tail of the pancreas and is much more common in women than in men (~20:1). (48-50)

Some patients are found to have an MCN incidentally during abdominal imaging, but patients with an MCN can also present with abdominal pain or the feeling of abdominal fullness. Because MCNs do not communicate with the ductal system, patients with an MCN are less likely to present with pancreatitis, jaundice, or new-onset diabetes mellitus than are patients with an IPMN. (49) Radiologic features that favor a diagnosis of MCN include a solitary cyst with thick cyst walls, internal septations, and peripheral calcifications. (15) As previously described, the cytologic features of MCN are similar to those of IPMN, and it is therefore difficult to distinguish MCN from IPMN based on cytologic features alone. The ovarian-type stroma of an MCN that is seen on histology is rarely encountered on a cytology sample. Cytology can, however, confirm the presence of a mucin-producing cyst using the criteria discussed in the above section on IPMNs.

Risk of Invasive Carcinoma.--Mucinous cystic neoplasms have an associated invasive PDAC in approximately 15% to 30% of cases, but the risk of invasion can be adjusted for a particular patient based on clinical, imaging, cytology, and surgical pathology findings. (15,20,50) In general, increasing age is a risk factor for invasive PDAC arising from an MCN. This relationship of carcinoma with age is not surprising given that MCN is a known precursor of invasive PDAC. (15,49,51) On imaging studies, larger cyst size, thickening of the septations within an MCN, and presence of an intracystic or adjacent solid mass are radiologic features that may suggest an associated invasive PDAC. (15,50,52) The cytopathologic features that are worrisome for invasive carcinoma arising from an MCN are similar to those for IPMN: nucleomegaly, clumped and irregular chromatin distribution, irregular nuclear contours, and crowding.

As was true for IPMNs, once resected, the single most important factor for the pathologist to determine is the presence or absence of an associated invasive carcinoma. On sectioning of the specimen, a solid stromal component or an intracystic nodule, often with papillary features, is commonly associated with an invasive component. High-grade dysplasia is a histologic feature that raises concern for an adjacent invasive PDAC, as is the loss or effacement of the classic ovarian-type stroma beneath the mucinous epithelium. For these reasons, extensive, if not complete, sampling of the cyst wall and of any nodular areas adjacent to the cyst is necessary to fully rule out the presence of invasion. (50) Noninvasive MCNs are graded as low- or high-grade neoplasms, with those formerly considered intermediate grouped in the low-grade category based on the recommendations of an expert panel. (28)

Clinical Outcome and Management Recommendations.--Standard of care for MCN is usually a distal pancreatectomy with a lymph node dissection. (20) Patients who are found to have only noninvasive MCN on the resection specimen do not need any additional follow-up, because, in contrast to IPMNs, MCNs are solitary lesions and the 5-year overall survival rate for a patient with noninvasive MCN approaches 100%. The presence of an associated invasive PDAC lowers the 5-year survival to 25% to 35%. (20,50,51) The presence of minimally invasive carcinoma, defined in these cases as microscopic foci of adenocarcinoma that do not invade the pancreatic parenchyma but are limited to the ovarian stroma of the MCN, confers an excellent prognosis. Although minimally invasive carcinoma is likely cured by resection, these lesions may rarely recur. (53) Again, this underscores the importance of extensive sampling of the cyst wall for accurate diagnosis and prognostication.

Genetic Alterations and Molecular Diagnostics.--Activating point mutations in KRAS are an early genetic alteration in the development of MCN, whereas inactivation of TP53 and SMAD4 occur as late events. These alterations are similar to those found in other epithelial neoplasms of the pancreas, and therefore are not specific markers for MCN. In fact, presurgical diagnosis of MCN often relies on what is not present in the cyst, rather than what is: MCN does not have a specific genetic mutation, it does not communicate with the main pancreatic duct, and it does not present as multiple cysts. (39)

Intraductal Tubulopapillary Neoplasm

Because a comprehensive review of intraductal tubulopapillary neoplasm was recently published in this journal, only a brief mention of this precursor will be made here. (54) Intraductal tubulopapillary neoplasms are grossly visible neoplasms that communicate with the pancreatic ductal system, grow in a tubular pattern, and often have highgrade dysplasia and comedo-like necrosis. Because this is an uncommon entity, data on molecular diagnostics and clinical prognosis are limited.


Although the above sections have focused on grossly visible precursor lesions, the remainder of the review will cover what is known about the microscopic and noncystic lesion known as pancreatic intraepithelial neoplasia (PanIN). Because PanIN is microscopic and often multifocal, it cannot be treated with surgical resection in the manner of a cyst, even though we now believe that most PDACs arise from PanIN lesions. Nevertheless, understanding the stepwise molecular changes that occur in the transformation of normal ductal epithelium through the stages of PanIN to invasive cancer provides insight not only into potential treatments for PDAC, but also into the molecular machinery of invasive malignancy. Because the research available on molecular changes in PanIN is vast, only the most common genetic mutations and deletions will be discussed below.

Histologic Identification and Clinical Relevance

Pancreatic intraepithelial neoplasias have been recognized histologically for more than a century as lesions histologically distinct from the cuboidal cells of normal ductal epithelium (Figure 4, a). Although a variety of terms have been given to PanIN lesions, consensus has been reached on both terminology and grading of this histologically identifiable lesion. (55,56) The grading system originally proposed for PanIN was a 3-tiered system based on nuclear and architectural features. The first tier was stratified by architecture. Pancreatic intraepithelial neoplasia 1A consists of flat ductal lesions with columnar cells that have small, basally located nuclei. Pancreatic intraepithelial neoplasia 1B has the same cytologic features, but allows for papillary or micropapillary architecture (Figure 4, b). Pancreatic intraepithelial neoplasia 2 has nuclear atypia including loss of polarity, nuclear crowding, and some hyperchromasia with either a flat or papillary architecture (Figure 4, c), whereas PanIN-3 is almost always papillary or micropapillary, may have cribriforming, and has marked nuclear atypia that exceeds that seen in PanIN-2, and may also include macronucleoli and abnormal mitotic figures (Figure 4, d).

Recently, a simplified 2-tier classification has been proposed for both PanIN and IPMN. In this system, PanIN-1 and PanIN-2 are considered low grade and PanIN-3 is termed high grade. (28) This change in terminology is largely based on clinical relevance of PanIN lesions. In surgically resected specimens, the presence of Pan-IN 1 or 2 (low-grade PanIN), even when present at a surgical resection margin, has not been correlated with the presence of residual or recurrent PDAC in the remnant pancreas. Pancreatic intraepithelial neoplasia 3 (high-grade PanIN), on the other hand, is frequently found in the presence of invasive PDAC, and should therefore be reported. (28,57,58) In fact, lesions called PanIN-3 may sometimes represent "cancerization of ducts," or intraductal spread of an invasive PDAC. Adequate sampling of the pancreas should be able to confirm the presence of the invasive component. (28)

Pancreatic intraepithelial neoplasia lesions are often surrounded by lobular parenchymal atrophy. (59,60) When atrophy is multifocal, or solitary of sufficient size, it may be detected on endoscopic ultrasound. In patients at high risk for PDAC, such as those with a strong family history or known genetic risk factor, multifocal atrophy may serve as a surrogate for multifocal PanIN lesions and possible risk of PDAC. Studies suggest that the progression from initial mutation within a pancreatic cell to the invasive event of malignancy takes at least a decade, if not longer. (2,61) Screening a selected subset of the population at risk, then, may actually allow for detection and treatment of high-grade PanIN lesions prior to invasion. (1,59,62)

Common Genetic Alterations

The genetic changes identified in PanIN correlate with the progression of histologic dysplasia. The earliest alterations found in low-grade PanIN lesions are shortening of telomeres and activating point mutations in KRAS. (63-66) Telomeres are repeated sequences at the ends of chromosomes that are responsible for maintaining the integrity of the genomic material by prevention of breakage during cell division. Telomere shortening and abnormalities of telomerase activity have been identified in a variety of cancers. (66,67)

Mutated KRAS proteins allow for dysregulation and constitutive signaling activation within the mitogen-activated protein kinase and AKT signaling cascades. (68) Mouse models have shown that the KRAS G12D mutation is sufficient for producing PanIN lesions that spontaneously progress to invasive carcinoma, and studies of human PDAC tissues have repeatedly shown that KRAS codon 12 mutations are highly prevalent in low-grade PanIN as well as high-grade lesions and invasive PDAC. (64,69-71)

Mutations in the tumor suppressor gene CDKN2A usually occur after KRAS mutations, and therefore are more prevalent in high-grade than in low-grade PanIN lesions. (68,71) The protein product of CDKN2A, p16, is a necessary component of the cell cycle that, under normal conditions, inhibits cyclin D1. In PanIN and PDAC pathogenesis, p16 function may be lost secondary to deletion or promoter methylation silencing of CDKN2A. (72,73) Immunohistochemical studies, where nuclear p16 loss serves as a surrogate for CDKN2A loss or silencing, have demonstrated that cell cycle dysregulation is present in a subset of PanIN lesions in the setting of chronic pancreatitis, and have confirmed that the prevalence of cell cycle dysregulation increases with increasing histologic dysplasia. (74,75)

Finally, the mutations that are found almost exclusively in high-grade PanINs (and invasive PDAC) occur in the tumor suppressor genes TP53 and SMAD4. (63,64,76) Under normal conditions, the p53 protein is necessary for several vital cell functions, including the cell cycle, DNA repair, and the apoptotic pathway. Without functional p53, cells may continue to proliferate, even if they are damaged. Loss of p53 is almost always due to loss of one TP53 allele and mutation of the second allele. (68,77) SMAD4/DPC4 is lost in a similar manner to TP53, although homozygous deletion of the gene also may occur. Without a functional Smad4/Dpc4 protein, the transforming growth factor [beta] signaling pathway is interrupted, and tumor growth can continue unchecked. SMAD4 gene inactivation or deletion is associated with a worse prognosis in invasive PDAC. (78)

As with the previously mentioned cyst fluid studies for IPMN, techniques to collect pancreatic juice fluid endoscopically from the duodenum and analyze it for mutations common to PanIN and PDAC are in development. Currently, KRAS mutations and elevated telomerase activity can be identified in pancreatic secretions of patients who are known to have PDAC. (47,79) A small proportion of patients who are "normal controls" have also been found to harbor KRAS mutations. (79) Presumably, these control patients have PanINs that may one day be able to be followed with enhanced imaging and secretion analysis with the goal of preventing progression to invasive carcinoma.


A note about acinar-ductal metaplasia and atypical flat lesions is warranted so that the reader is familiar with these terms. Both acinar-ductal metaplasia and atypical flat lesions have been identified in mouse models of PDAC and the pancreata of human patients who have a familial predisposition to PDAC. (28) Because these lesions sometimes harbor KRAS mutations, it is thought that they may represent a metaplastic-dysplastic sequence, but as of yet the true clinical significance of these histologic entities is unknown. (80,81)


Overall, the focus of this review has been on the importance of PDAC precursors as they relate to improved therapies for patients. The timely recognition of PDAC precursors through imaging and cytopathology may allow for intervention before these lesions progress to an invasive malignancy. The single most important issue in evaluating surgical resection specimens is determining whether or not there is an associated invasive carcinoma. Finally, increased knowledge of the molecular alterations and pathways involved in the progression from precursor to invasive malignancy will hopefully lead to new, targeted therapies for patients with PDAC.


(1.) Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-2921. doi:10.1158/0008-5472.CAN-14-0155.

(2.) Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-1117. doi: 10.1038/nature09515.

(3.) Kloppel G, Basturk O, Schlitter AM, Konukiewitz B, Esposito I. Intraductal neoplasms of the pancreas. Semin Diagn Pathol. 2014;31(6):452-466. doi:10.1053/j.semdp.2014.08.005.

(4.) Bosman FT, World Health Organization, International Agency for Research on Cancer, eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press;2010.

(5.) D'Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg. 2004;239(3):400-408.

(6.) de Wilde RF, Hruban RH, Maitra A, Offerhaus GJA. Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm. Diagn Histopathol. 2012;18(1): 17-30.

(7.) Rezaee N, Barbon C, Zaki A, et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB (Oxford). 2016;18(3):236-246. doi:10.1016/j.hpb.2015.10.010.

(8.) Hruban RH, Pitman MB, Klimstra DS. Tumors of the Pancreas. Washington, DC: American Registry of Pathology and Armed Forces Institute of Pathology; 2007. AFIP Atlas of Tumor Pathology; 4th series, fascicle 6.

(9.) Silas AM, Morrin MM, Raptopoulos V, Keogan MT. Intraductal papillary mucinous tumors of the pancreas. Am J Roentgenol. 2001;176(1):179-185. doi: 10.2214/ajr.176.1.1760179.

(10.) Yamao K, Ohashi K, Nakamura T, et al. Evaluation of various imaging methods in the differential diagnosis of intraductal papillary-mucinous tumor (IPMT) of the pancreas. Hepatogastroenterology. 2001;48(40):962-966.

(11.) Bellizzi AM, Stelow EB. Pancreatic cytopathology: a practical approach and review. Arch Pathol Lab Med. 2009;133(3):388-404. doi:10.1043/15432165-133.3.388.

(12.) Genevay M, Mino-Kenudson M, Yaeger K, et al. Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg. 2011;254(6):977-983. doi:10.1097/SLA.0b013e3182383118.

(13.) Stelow EB, Shami VM, Abbott TE, et al. The use of fine needle aspiration cytology for the distinction of pancreatic mucinous neoplasia. Am J Clin Pathol. 2008;129(1):67-74. doi:10.1309/Y16QCXE3YGMXX19Q.

(14.) Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126(5):1330-1336.

(15.) Brugge WR. Diagnosis and management of cystic lesions of the pancreas. J Gastrointest Oncol. 2015;6(4):375-388. doi:10.3978/j.issn.2078-6891.2015.057.

(16.) Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer. 2002;94(1):62-77.

(17.) Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239(6):788-797; discussion 797-799.

(18.) Grutzmann R, Niedergethmann M, Pilarsky C, Kloppel G, Saeger HD. Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist. 2010;15(12):1294-1309. doi:10.1634/theoncologist. 2010-0151.

(19.) Strauss A, Birdsey M, Fritz S, et al. Intraductal papillary mucinous neoplasms of the pancreas: radiological predictors of malignant transformation and the introduction of bile duct dilation to current guidelines. Br J Radiol. 2016; 89(1061):20150853. doi:10.1259/bjr.20150853.

(20.) Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):1 83-197. doi:10.1016/j.pan.2012.04.004.

(21.) Anand N, Sampath K, Wu BU. Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(8):913-921. doi:10.1016/j.cgh.2013.02.010.

(22.) Raman SP, Kawamoto S, Blackford A, et al. Histopathologic findings of multifocal pancreatic intraductal papillary mucinous neoplasms on CT. AJRAm J Roentgenol. 2013;200(3):563-569. doi:10.2214/AJR.12.8924.

(23.) Adsay V, Mino-Kenudson M, Furukawa T, et al. Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: recommendations of Verona consensus meeting. Ann Surg. 2016;263(1):162-177. doi:10.1097/SLA.0000000000001173.

(24.) Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977-987.

(25.) Schaberg KB, DiMaio MA, Longacre TA. Intraductal papillary mucinous neoplasms often contain epithelium from multiple subtypes and/or are unclassifiable. Am J Surg Pathol. 2016;40(1):44-50. doi:10.1097/PAS.0000000000000528.

(26.) Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011; 60(4):509-516. doi:10.1136/gut.2010.210567.

(27.) Distler M, Kersting S, Niedergethmann M, et al. Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 2013;258(2):324-330. doi:10.1097/SLA.0b013e318287ab73.

(28.) Basturk O, Hong S-M, Wood LD, et al. A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am I Surg Pathol. 2015;39(12):1730-1741. doi:10.1097/PAS.0000000000000533.

(29.) Marchegiani G, Mino-Kenudson M, Ferrone CR, Warshaw AL, Lillemoe KD, Fernandez-del Castillo C. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg. 2015;220(5):839-844. doi:10.1016/j.jamcollsurg.2015.01.051.

(30.) Basturk O, Tan M, Bhanot U, et al. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol. 2016;29(9):1058-1069. doi:10.1038/modpathol.2016.98.

(31.) Koh Y-X, Chok A-Y, Zheng H-L, Tan C-S, Goh BKP. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2014;21(8):2782-2800. doi:10.1245/s10434-014-3639-0.

(32.) Pea A, Yu J, Rezaee N, et al. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas [published online ahead of print July 18, 2016]. Ann Surg. doi:10.1097/SLA.0000000000001817.

(33.) He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216(4):657-665; discussion 665-667. doi:10.1016/j.jamcollsurg.2012.12.026.

(34.) Miyasaka Y, Ohtsuka T, Tamura K, et al. Predictive factors for the metachronous development of high-risk lesions in the remnant pancreas after partial pancreatectomy for intraductal papillary mucinous neoplasm. Ann Surg. 2016;263(6):1180-1187. doi:10.1097/SLA.0000000000001368.

(35.) Turrini O, Waters JA, Schnelldorfer T, et al. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford). 2010;12(7):447-455. doi:10.1111/j.1477-2574.2010.00196.x.

(36.) Hirono S, Kawai M, Okada K-I, et al. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2016;160(2):306-317. doi:10.1016/j.surg.2016.04.007.

(37.) Matthaei H, Wu J, Dal Molin M, et al. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs." Am J Surg Pathol. 2014;38(3):360-363. doi:10.1097/PAS.0000000000000117.

(38.) Gaujoux S, Salenave S, Ronot M, et al. Hepatobiliary and pancreatic neoplasms in patients with McCune-Albright syndrome. J Clin Endocrinol Metab. 2014;99(1):E97-E101. doi:10.1210/jc.2013-1823.

(39.) Springer S, Wang Y, Dal Molin M, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015;149(6):1501-1510. doi:10.1053/j.gastro.2015.07.041.

(40.) Tan MC, Basturk O, Brannon AR, et al. GNAS and KRAS mutations define separate progression pathways in intraductal papillary mucinous neoplasm-associated carcinoma. J Am Coll Surg. 2015;220(5):845-854.e1. doi:10.1016/j.jamcollsurg.2014.11.029.

(41.) Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999;154(6):1835-1840. doi:10.1016/S0002-9440(10)65440-5.

(42.) Furukawa T, Fujisaki R, Yoshida Y, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol. 2005;18(8):1034-1042. doi:10.1038/modpathol.3800383.

(43.) Schonleben F, Qiu W, Ciau NT, et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res. 2006; 12(12):3851-3855. doi:10.1158/1078-0432.CCR-06-0292.

(44.) Amato E, Molin MD, Mafficini A, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol. 2014;233(3):217-227. doi:10.1002/path.4344.

(45.) Singhi AD, Nikiforova MN, Fasanella KE, et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res. 2014;20(16):4381-4389. doi:10.1158/1078-0432.CCR-14-0513.

(46.) Yu J, Sadakari Y, Shindo K, et al. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms [published online ahead of print July 18, 2016]. Gut. doi: 10.1136/gutjnl-2015-311166.

(47.) Hata T, Dal Molin M, Suenaga M, et al. Cyst fluid telomerase activity predicts the histologic grade of cystic neoplasms of the pancreas. Clin Cancer Res. 2016;22(20):5141-5151. doi:10.1158/1078-0432.CCR-16-0311.

(48.) Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. Gastroenterol Clin North Am. 2007;36(4):831-849, vi. doi:10.1016/j.gtc.2007.08.012.

(49.) Crippa S, Fernandez-Del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol. 2010;8(2):213-219. doi:10.1016/j.cgh.2009.10.001.

(50.) Jang K-T, Park SM, Basturk O, et al. Clinicopathologic characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma: implications for management and prognosis. Am J Surg Pathol. 2015;39(2):179-187. doi:10.1097/PAS.0000000000000357.

(51.) Sarr MG, Carpenter HA, Prabhakar LP, et al. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg. 2000;231(2):205-212.

(52.) Di Paola V, Manfredi R, Mehrabi S, et al. Pancreatic mucinous cystoadenomas and cystoadenocarcinomas: differential diagnosis by means of MRI. Br J Radiol. 2016;89(1057):20150536. doi:10.1259/bjr.20150536.

(53.) Lewis GH, Wang H, Bellizzi AM, et al. Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2013;37(4):601-605. doi:10.1097/PAS.0b013e318273f3b0.

(54.) Rooney SL, Shi J. Intraductal tubulopapillary neoplasm of the pancreas. Arch Pathol Lab Med. 2016;140(10):1068-1073.

(55.) Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol. 1998;22(2):163-169.

(56.) Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25(5):579-586.

(57.) Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol. 2003;16(10):996-1006. doi:10.1097/01.MP.0000087422.24733.62.

(58.) Matthaei H, Hong S-M, Mayo SC, et al. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Ann Surg Oncol. 2011; 18(12):3493-3499. doi:10.1245/s10434-011-1745-9.

(59.) Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30(9):1067-1076. doi: pas.0000213265.84725.0b.

(60.) Detlefsen S, Sipos B, Feyerabend B, Kloppel G. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch Int J Pathol. 2005;447(5):800-805. doi:10.1007/s00428-005-0032-1.

(61.) lacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2012;61(7): 1085-1094. doi:10.1136/gut.2010.236026.

(62.) Canto Ml, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339-347. doi: 10.1136/gutjnl-2012-303108.

(63.) Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6(8):2969-2972.

(64.) Murphy SJ, Hart SN, Lima JF, et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology. 2013;145(5):1098-1109.e1. doi:10.1053/j.gastro.2013.07.049.

(65.) Hong S-M, Heaphy CM, Shi C, et al. Telomeres are shortened in acinar-toductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Mod Pathol. 2011;24(2):256-266. doi:10.1038/modpathol.2010.181.

(66.) van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol. 2002;161(5):1541-1547. doi:10.1016/S0002-9440(10)64432-X.

(67.) Basu N, Skinner HG, Litzelman K, Vanderboom R, Baichoo E, Boardman LA. Telomeres and telomere dynamics: relevance to cancers of the Gl tract. Expert Rev Gastroenterol Hepatol. 2013;7(8):733-748. doi:10.1586/17474124.2013.848790.

(68.) Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg. 2007;14(3):224-232. doi:10.1007/s00534-006-1166-5.

(69.) Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6): 437-450.

(70.) Qiu W, Sahin F, lacobuzio-Donahue CA, et al. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget. 2011;2(11):862-873. doi:10.18632/oncotarget.357.

(71.) Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142(4):730-733.e9. doi:10.1053/j.gastro.2011.12.042.

(72.) Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8(1):27-32. doi:10.1038/ng0994-27.

(73.) Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60(7):1835-1839.

(74.) Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res. 1998;58(20):4740-4744.

(75.) Rosty C, Geradts J, Sato N, et al. p16 lnactivation in pancreatic intraepithelial neoplasias (PanlNs) arising in patients with chronic pancreatitis. Am J Surg Pathol. 2003;27(12):1495-1501.

(76.) Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16(9):902-912. doi:10.1097/01. MP.0000086072.56290.FB.

(77.) Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54(11):3025-3033.

(78.) Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Am Assoc Cancer Res. 2009;15(14):4674-4679. doi:10.1158/1078-0432.CCR-09-0227.

(79.) Eshleman JR, Norris AL, Sadakari Y, et al. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol. 2015;13(5):963-969.e4. doi:10.1016/j.cgh.2014.11.028.

(80.) De La O JP, Emerson LL, Goodman JL, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2008;105:18907-18912.

(81.) Aichler M, Seiler C, Tost M, et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol. 2012;226(5):723-734.

Meredith E. Pittman, MD; Rema Rao, MD; Ralph H. Hruban, MD

Accepted for publication May 4, 2017.

From the Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York (Drs Pittman and Rao); and the Department of Pathology (Dr Hruban) and the Sol Goldman Pancreatic Cancer Research Center (Dr Hruban), Johns Hopkins University School of Medicine, Baltimore, Maryland.

The authors have no relevant financial interest in the products or companies described in this article.

This research was supported by NIH grant P50CA62924.

Reprints: Meredith E. Pittman, MD, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, Starr 1031A, 525 E 68th St, New York, NY 1 0065 (email:

Caption: Figure 1. Cytologic features of neoplastic mucin-producing cysts. A, Thick extracellular (neoplastic) mucin. B, A case of intraductal papillary mucinous neoplasm (IPMN) showing mucinous glandular epithelial cells arranged in papillary clusters with low-grade atypia. C, A case of well-differentiated adenocarcinoma showing the loss of a regular honeycombed pattern (drunken honeycomb). D, A case of IPMN demonstrating high-grade dysplasia (Diff-Quik, original magnification 3400 [A and B]; Papanicolaou, original magnification 3400 [C and D]).

Caption: Figure 2. Gross and microscopic features of intraductal papillary mucinous neoplasms (IPMNs). A, A branch-duct IPMN with extension into and dilation of the side and main pancreatic ducts. B, The gastric histologic subtype has basally oriented nuclei and abundant foveolar-type mucin. Scattered goblet cells are allowed. C, The intestinal subtype has cigar-shaped, hyperchromatic, crowded nuclei and occasional goblet cells. D, The pancreatobiliary subtype is by definition high grade, both architecturally and cytologically (hematoxylin-eosin, original magnification X200 [B through D]).

Caption: Figure 3. A, Mucinous cystic neoplasms demonstrate a simple mucinous lining with cellular ovarian-type stroma underneath. B, Even when the cyst has been dilated and the epithelium attenuated, the ovarian stroma is the clue to the diagnosis. Normal pancreatic elements may be found within the cellular stroma (hematoxylin-eosin, original magnification X200).

Caption: Figure 4. Pancreatic intraepithelial neoplasia (PanIN) was previously subcategorized into 4 grades; now 2 grades, low and high, are recommended. A, A normal pancreatic duct without PanIN. B, A low-grade PanIN with the characteristic surrounding lobular atrophy. C, Another low-grade PanIN lesion. Looking at the horizontal ductal epithelium from left to right, you can see nonneoplastic epithelium, low-grade (formerly grade 1A) PanIN, and low-grade (formerly grade 2) PanIN. D, A view of high-grade PanIN (versus cancerization of ducts) with loss of nuclear polarity, hyperchromatic nuclei, and macronucleoli. High-grade PanIN is virtually always associated with invasive malignancy, as it was in this case (hematoxylin-eosin, original magnifications X100 [A], X40 [B], and X200 [C and D]).

[Please Note: Illustration(s) are not available due to copyright restrictions.]
COPYRIGHT 2017 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Pittman, Meredith E.; Rao, Rema; Hruban, Ralph H.
Publication:Archives of Pathology & Laboratory Medicine
Article Type:Report
Date:Dec 1, 2017
Previous Article:Current Concepts in Diagnosis, Molecular Features, and Management of Lobular Carcinoma In Situ of the Breast With a Discussion of Morphologic...
Next Article:Factor V Inhibitors: A Diagnostic and Therapeutic Challenge.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters